MILAN, Italy — The European Investment Bank has committed up to €20 million in convertible venture debt to Tensive, an Italian medical-technology company developing a bioresorbable implant intended to support breast-tissue restoration after lumpectomy.
The financing, announced on 3 September and backed by the European Union’s InvestEU programme, is expected to support clinical development, regulatory work, research and early industrialisation in Italy.
Tensive’s REGENERA and SOFTAG platform is designed for patients undergoing lumpectomy, a breast-conserving procedure in which a tumour and surrounding tissue are removed. The sponge-like scaffold is placed inside the surgical cavity and is intended to be gradually absorbed as the patient’s own tissue grows into the area.
The company says the implant can also be distinguished from surrounding tissue during diagnostic imaging, potentially supporting radiotherapy targeting and follow-up surveillance.
The technology remains under clinical development and is not commercially available. Tensive has said it anticipates an initial European regulatory decision as early as 2027.
Clinical findings reported by Tensive
Following questions raised in SheFront’s original coverage, Tensive directed the publication to clinical findings released in July 2026 and to its existing scientific publications.
According to the company’s 12-month update from its ongoing pivotal trial, 94 patients were enrolled, 87 had passed 12 months of follow-up and 30 had completed 24 months.
Tensive reported that patient-reported BREAST-Q scores showed statistically significant improvements from baseline in both Satisfaction with Breast and Cancer Worry at six and 12 months, with p-values below 0.001.
The company also reported good-to-excellent cosmetic outcomes in 94.2% of evaluable cases at 12 months. Investigator satisfaction averaged 8.6 on a 10-point scale at that stage.
No interference with oncologic imaging was reported on ultrasound, MRI or mammography.
Tensive disclosed one procedure-related adverse event involving post-radiotherapy redness and wound retraction that did not resolve over time. The company said the percentage of potentially related events remained below the trial’s pre-specified 5% safety threshold.
These 12-month findings are company-reported interim results. Tensive says the complete pivotal-trial dataset will be submitted for future peer-reviewed publication.
What has been peer-reviewed?
A peer-reviewed interim study published in Updates in Surgery in April 2026 examined the first 25 patients with six months of follow-up following breast-conserving surgery and whole-breast radiotherapy.
The study reported no major complications. All patients completed radiotherapy, while reported acute radiotherapy toxicity was limited to grades one and two. The researchers also reported favourable cosmetic outcomes, improvements in patient satisfaction and no significant interference with MRI follow-up.
However, the authors acknowledged that the clinical evidence remained limited and that longer-term evaluation would be required.
Tensive has also cited five-year findings from a separate first-in-human study involving patients treated following the removal of non-malignant breast lesions. Those findings indicated persistent volume replacement, vascularisation, gradual scaffold absorption and no capsule formation. Because that study involved non-malignant conditions, its results should not be treated as a substitute for long-term evidence from breast-cancer patients.
Why careful scrutiny still matters
Breast reconstruction is not merely a cosmetic issue. Changes following cancer surgery can affect comfort, clothing, sexuality, body image and a person’s sense of recovery. At the same time, no patient should be made to feel that reconstruction is necessary to appear “whole.”
The emerging evidence addresses several important questions about patient-reported satisfaction, radiotherapy tolerance, imaging and adverse events. It makes the clinical picture more developed than the original article indicated.
Nevertheless, regulatory approval, publication of the complete pivotal-trial results and longer follow-up among breast-cancer patients remain necessary before the implant’s long-term safety, durability and clinical role can be fully established.
The EIB investment is therefore significant support for further development, but it should not be interpreted as regulatory approval or an independent guarantee of clinical performance.
For women recovering from breast cancer, the technology may eventually provide an additional reconstruction option. The most responsible path is to recognise the encouraging evidence already available while continuing to demand transparent reporting, independent scrutiny and meaningful long-term patient outcomes.
Editor’s note: This article was updated on 9 September 2026 following clarification from Tensive. The revision adds company-reported 12-month pivotal-trial findings and relevant peer-reviewed evidence concerning patient-reported outcomes, radiotherapy, imaging and adverse events. The article continues to distinguish interim company-reported findings from fully published pivotal-trial results.
Join the discussion